News AnalysisRegulatory News How animal testing became a MAHA political wedge issueWhile cancer scientists say NIH, FDA moves are premature, animal rights advocates say changes aren’t drastic enough October 17, 2025Vol.51 No.38By Claire Marie Porter and Jacquelyn Cobb
Drugs & Targets FDA requires a boxed warning for immune effector cell-associated enterocolitis following Carvykti treatment October 17, 2025Vol.51 No.38
Drugs & Targets FDA approves Zepzelca + Tecentriq combination as first-line maintenance therapy for ES-SCLC October 03, 2025Vol.51 No.36
Drugs & Targets FDA approves Inluriyo for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer October 03, 2025Vol.51 No.36
Drugs & Targets FDA grants Fast Track Designation to UB-VV111 in vivo CAR T-cell therapy October 03, 2025Vol.51 No.36
Podcast With Anthony Letai’s appointment, NCI is now under new leadership—just in time for a shutdown October 01, 2025Vol.51 No.35
News AnalysisRegulatory News Trump’s FDA invents an unusual regulatory pathway to approve leucovorin for autismExperts call the move “extremely premature” September 26, 2025Vol.51 No.35By Claire Marie Porter and Paul Goldberg
Cancer Policy Trump claims that autism is caused by Tylenol use during pregnancy, advises to “fight like hell not to take it” September 26, 2025Vol.51 No.35By Claire Marie Porter
Drugs & Targets FDA approves Keytruda Qlex injection for subcutaneous use in 38 tumor indications September 26, 2025Vol.51 No.35By Jacquelyn Cobb
